Received May 12, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
an adult who received a dose of the pediatric; an adult who received a dose of the pediatric; This non-serious case was reported by a pharmacist via sales rep and described the occurrence of adult use of a child product in a adult patient who received HBV (Engerix B pediatric) for prophylaxis. On an unknown date, the patient received the 1st dose of Engerix B pediatric. On an unknown date, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: an adult who received a dose of the pediatric) and underdose (Verbatim: an adult who received a dose of the pediatric). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 04-MAY-2026 The reporter reported that an adult who received a dose of the pediatric, then the reporter asked if she could administer a second dose of the pediatric to equal the adult dose. The batch number was not provided and a request for this information has been made.